ProCE Banner Activity

KEYNOTE-042: First-line Pembrolizumab vs Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC With PD-L1 TPS ≥ 1%

Slideset Download
Conference Coverage
In this planned interim analysis, first-line pembrolizumab significantly improved OS vs CT in patients with NSCLC and PD-L1 TPS ≥ 1% with a 19% reduced risk of death.

Released: June 13, 2018

Expiration: June 12, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen